{"id":76309,"title":"Novacyt S.A. (NCYT.L) Director/PDMR Shareholding","publisher":"Share Talk","author":"sharetalk","published":"2020-11-12T08:28:22+00:00","modified":"2020-11-12T08:28:22+00:00","canonical_url":"https://www.share-talk.com/novacyt-s-a-ncyt-l-director-pdmr-shareholding/","markdown_url":"https://www.share-talk.com/novacyt-s-a-ncyt-l-director-pdmr-shareholding.md","json_url":"https://www.share-talk.com/novacyt-s-a-ncyt-l-director-pdmr-shareholding.json","category":"Healthcare","categories":["Healthcare"],"tags":["development","diagnostic","diagnostics","Graham Mullis","haematology","IT-IS","IT-IS International Ltd","Lab21","Lab21 Products","microbiology","molecular","NCYT","Novacyt S.A.","Primerdesign","product","Roderic Fuerst","serology","serology markets","vitro"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"Paris, France and Camberley, UK – 12 November 2020 – **Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT)**, an international specialist in clinical diagnostics, announces that it has been notified that, on 11 November 2020.\n\n**Graham Mullis, Chief Executive of the Company**, acquired 60,875 ordinary shares of €1/15 each in the Company at a price of £8.17 per share.  The resultant beneficial shareholding of Mr Mullis is 122,506 ordinary shares representing 0.17% of the Company’s issued share capital.\n\n \n\nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them\n\n \n\n|   |   |   |   |\n| --- | --- | --- | --- |\n| 1. | Details of the person discharging managerial responsibilities / person closely associated |  |  |\n| a) | Name |   Graham Mullis, Chief Executive Officer   |  |\n| 2. | Reason for the Notification |  |  |\n| a) | Position/status | See 1(a) – classified as a PDMR of the Company   |  |\n| b) | Initial notification/ Amendment | Initial Notification   |  |\n| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |  |  |\n| a) | Name | Novacyt S.A. |  |\n| b) | LEI | 213800BWAC2BF295EG28 |  |\n| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |  |  |\n| a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each   |  |\n|  | Identification code | FR0010397232 |  |\n| b) | Nature of the transaction | Acquisition of Ordinary Shares   |  |\n| c) | Price(s) and volume(s) |   Price | Volume |\n| £8.17 | 60,875 |  |  |\n\nd)\n\nAggregated information:\n\n· Aggregated volume\n\n· Price\n\n \n\n|   |   |\n| --- | --- |\n| Price | Volume |\n| £8.17 | 60,875 |\n\n \n\n \n\ne)\n\nDate of the transaction\n\n \n\n11 November 2020\n\nf)\n\nPlace of the transaction\n\nLondon Stock Exchange, AIM\n\n**Contacts**\n\n**Novacyt SA**\n\n**Graham Mullis, Chief Executive Officer**\n\n**Anthony Dyer, Chief Financial Officer**\n\n**+44 (0)1276 600081**"}